Fusion Antibodies recovers from disappointing first six months of the financial year
Pharmaceutical research firm Fusion Antibodies - one of Northern Ireland's most recent publicly listed companies - has reported revenue growth to £1.5m in the second half of the year.
The Belfast-based firm, which floated on the Alternative Investment Market during 2017, said revenues for the full year ending March 31 were expected to be £2.2m.
The company, headed by chief executive Paul Kerr, yesterday released its yearly trading update.
Fusion Antibodies said revenues and orders picked up significantly from October 2018 onwards, following a disappointing first six months of the 2019 financial year.
Total orders for the second half of the 2019 financial year were £2.1m. The company said revenues for the period are expected to be £1.5m, returning to the levels seen in the second half of the 2018 financial year (£1.3m), but significantly ahead of the £700,000 recorded in first half of 2019.
Fusion said the improvement in the second six months had been achieved by a mix of factors including addressing the external competitive pressures seen towards the end of the second half of 2018 and in the first six months of the 2019 financial year.
Please log in or register with belfasttelegraph.co.uk for free access to this article.